158 related articles for article (PubMed ID: 9191121)
21. Phosphodiesterase type 4 that regulates cAMP level in cortical neurons shows high sensitivity to rolipram.
Yamashita N; Yamauchi M; Baba J; Sawa A
Eur J Pharmacol; 1997 Oct; 337(1):95-102. PubMed ID: 9389386
[TBL] [Abstract][Full Text] [Related]
22. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
23. Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea.
Ellis JL; Conanan ND
J Pharmacol Exp Ther; 1995 Mar; 272(3):997-1004. PubMed ID: 7891355
[TBL] [Abstract][Full Text] [Related]
24. Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase.
Livi GP; Kmetz P; McHale MM; Cieslinski LB; Sathe GM; Taylor DP; Davis RL; Torphy TJ; Balcarek JM
Mol Cell Biol; 1990 Jun; 10(6):2678-86. PubMed ID: 2160582
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
Barnette MS; Grous M; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 Jun; 273(3):1396-402. PubMed ID: 7791113
[TBL] [Abstract][Full Text] [Related]
26. [3H]Rolipram binding and phosphodiesterase activity in neuroblastoma N18TG-2 and glioma C6Bu-1.
Tohda M; Murayama T; Hasegawa H; Nogiri S; Nomura Y
Neurosci Lett; 1994 Jul; 175(1-2):89-91. PubMed ID: 7526296
[TBL] [Abstract][Full Text] [Related]
27. Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D.
Wang P; Myers JG; Wu P; Cheewatrakoolpong B; Egan RW; Billah MM
Biochem Biophys Res Commun; 1997 May; 234(2):320-4. PubMed ID: 9177268
[TBL] [Abstract][Full Text] [Related]
28. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
Castro A; Jerez MJ; Gil C; Martinez A
Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
[TBL] [Abstract][Full Text] [Related]
29. Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phosphodiesterase (PDE IVD).
Baecker PA; Obernolte R; Bach C; Yee C; Shelton ER
Gene; 1994 Jan; 138(1-2):253-6. PubMed ID: 8125310
[TBL] [Abstract][Full Text] [Related]
30. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression.
Essayan DM; Huang SK; Kagey-Sobotka A; Lichtenstein LM
J Allergy Clin Immunol; 1997 Jan; 99(1 Pt 1):28-37. PubMed ID: 9003208
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain.
Iona S; Cuomo M; Bushnik T; Naro F; Sette C; Hess M; Shelton ER; Conti M
Mol Pharmacol; 1998 Jan; 53(1):23-32. PubMed ID: 9443929
[TBL] [Abstract][Full Text] [Related]
32. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G
Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161
[TBL] [Abstract][Full Text] [Related]
33. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
[TBL] [Abstract][Full Text] [Related]
34. Interferon-gamma and lipopolysaccharide reduce cAMP responses in cultured glial cells: reversal by a type IV phosphodiesterase inhibitor.
Patrizio M; Costa T; Levi G
Glia; 1995 Jun; 14(2):94-100. PubMed ID: 7558245
[TBL] [Abstract][Full Text] [Related]
35. Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis.
Greten TF; Sinha B; Haslberger C; Eigler A; Endres S
Eur J Pharmacol; 1996 Mar; 299(1-3):229-33. PubMed ID: 8901027
[TBL] [Abstract][Full Text] [Related]
36. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
Sutor B; Mantell K; Bacher B
Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
[TBL] [Abstract][Full Text] [Related]
37. The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains.
Beard MB; O'Connell JC; Bolger GB; Houslay MD
FEBS Lett; 1999 Oct; 460(1):173-7. PubMed ID: 10571082
[TBL] [Abstract][Full Text] [Related]
38. Cytochemical distribution of cyclic AMP-dependent 3',5'-nucleotide phosphodiesterase in the rat myocardium.
Okruhlicová L; Tribulová N; Eckly A; Lugnier C; Slezák J
Histochem J; 1996 Mar; 28(3):165-72. PubMed ID: 8735283
[TBL] [Abstract][Full Text] [Related]
39. Role of conserved histidines in catalytic activity and inhibitor binding of human recombinant phosphodiesterase 4A.
Jacobitz S; Ryan MD; McLaughlin MM; Livi GP; DeWolf WE; Torphy TJ
Mol Pharmacol; 1997 Jun; 51(6):999-1006. PubMed ID: 9187266
[TBL] [Abstract][Full Text] [Related]
40. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse.
Cherry JA; Thompson BE; Pho V
Biochim Biophys Acta; 2001 Mar; 1518(1-2):27-35. PubMed ID: 11267656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
